No Orkambi Deal Yet For England, But Vertex’ Portfolio Approach Still On The Table
Dialogue between Vertex and NHS England over cystic fibrosis drug Orkambi are set to continue after productive talks on April 25.
You may also be interested in...
The increasingly public row between Vertex and NHS England continues as NHS England claims it has offered Vertex the “largest ever financial commitment of its type” in its 70-year history. Meanwhile, Vertex has revealed that the NHS has offered a price that is significantly lower than the list price.
Talks between NHS England and Vertex over cystic fibrosis drug Orkambi are yet to bear fruit, but further discussions could take place next week.
Vertex Pharmaceuticals and NHS England are due to meet this week to see whether they can resolve their pricing deadlock over the cystic fibrosis drug Orkambi. Meanwhile, UK ministers are urging the company to bring these negotiations to an urgent resolution.